Dr. Keith Terasaki Chairman Terasaki Institute for Biomedical Innovation (TIBI), Dr. Mary Lou Jepsen CEO / Founder OPENWATER, and Dr. Xiling Shen CEO / Founder Xilis Inc — catalysts for radical biomedical innovation for the world’s 8 plus billion. Dr. Terasaki, Dr. Jepsen, and Dr. Shen are featured in three hour long video unscripted interviews describing their work and profound impact on global health.
TIBI, which has their Innovation Summit in March 2023 at UCLA’s Luskin Conference Center, performs ground-breaking translational research founded on their top-tier expertise in engineering, material science, biomedical implants, immunology, organs on a chip, stem cells and other technologies. Examples would be growing cultured meat to address global nutrition needs; developing organs on a chip such as a lymph node on a chip that helps predict how a person’s immune response may respond to a pathogen; creating wearable sensors to monitor important biomarkers of disease; they are working with stem cells and developing biological implants to help with healing, treating bone and heart conditions, assisting blood clotting, and for controlled drug release.
OPENWATER, uses new generation portable wearable devices that are precise, non-surgical, non drugs, low cost, AI-assisted — breakthrough phase-wave chip medical imaging technology and therapeutic devices that revolutionizes delivery care to patients. Their technology enables rapid identification of strokes (large vessel occlusions) to decrease the time to intervention in stroke victims, saving lives. Their devices allow therapeutic interventions for Alzheimer’s Disease, Cancer, and Neuropsychiatric Diseases like Depression and Anxiety.
Xilis, has the ability to test a patient’s cancer cells, which can predict which chemotherapy agent will work best. Xilis’ proprietary MicroOrganoSphereTM (MOS) technology retains unique patient tissue structure, genetic alterations, gene expression, immune microenvironment and histopathology. They can test hundreds of different chemotherapy agents and combinations of agents on a tumor biopsy sample, and get results quickly within two weeks. This would allow the initial treatment of a patient’s cancer with the precise agent that has the best chance of success. This method is being tried right now in multiple cancer centers around the world, with good initial success. This technique will revolutionize the way that chemotherapy is chosen for cancer patients. In addition, Xilis’ technology enables drug developers to scale and streamline all phases of preclinical and clinical development, resulting in more efficient use of resources.
[This article is driven by my global insights from working daily pro bono with more than one million CEOs, investors, scientists, and experts across 100+ projects.]
INTERVIEWS WITH DR. KEITH TERASAKI, DR. MARY LOU JEPSEN, DR. XILING SHEN
The interviews are with the non-profit IEEE TEMS (see interview series – Stephen Ibaraki – “Transformational Leadership and Innovation…”).
HAS Chat with Keith Terasaki, MD: Interventional radiologist, past chief of radiology Kaiser Hospital LA Medical Center; Chairman of Board Terasaki Foundation; Chairman Board Terasaki Institute for Biomedical Innovation; Chairman Board Wesley Health Clinics; Board member Colburn School of Music, Metropolitan YMCA, UCLA Life Sciences — about developing life-changing products in precision / personalized health, nutrition, and medicine leveraging translational interdisciplinary research leveraging transformational innovation in biomedical engineering, computing science, life sciences and more; serving diversity, equity, inclusion, accessibility, fundamental education for all.
I was born in Los Angeles, California. I attended UCLA for undergraduate and medical school. I became an interventional radiologist, after completing a fellowship at Stanford University. I have worked at the Kaiser Los Angeles Medical Center for over 25 years, where I was chief of the radiology department from 2003 to 2013.
My father, the late Paul Terasaki, was a medical researcher at UCLA. He performed a lot of the groundbreaking basic science work in organ transplantation over a 50 year career. He started the Terasaki Research Institute, where he continued research in organ transplantation. This is a non-profit research institute, located in Los Angeles, now with around 50 researchers.
After he passed away, we hired a new CEO at the Institute, Dr. Ali Khademhousseini. Under his leadership, the Institute has focused on innovation, trying to develop life-changing products in health and medicine.
One example of a product being developed at our institute is a test on cancer cells that can predict how well different chemotherapy agents will kill the tumor cells. This procedure is now being tested in multiple medical centers, and hopefully in the future will change how chemotherapy agents are chosen for patients.
Another example we are currently working on is growing cultured meat. We start with a muscle biopsy of a cattle, and then grow it in culture to make a hamburger. Right now, we can grow 200 liters of meat in an incubator tank in one week. We are working on scaling up our operations.
There are two potential huge benefits to our project. If we can grow enough cultured meat, and get people to consume it rather than regular meat, we can decrease the world need for agricultural space. We hope to see less farmlands, less water usage, less methane production, less pesticides and less slaughtering of cattle for food. This could lead to improved climate control. There are also huge potential health advantages of cultured meat. Someone can eat a hamburger made of pure myocytes, with little of the grease, saturated fat or cholesterol.
We have many other research projects going on at our institute, such as in stem cell research, organs on a chip, wearable sensors, biological implants, and vaccines that don’t need refrigeration. Our family foundation funds approximately half of the research performed at the Institute. For our family, it has been gratifying and exciting to see what can be done.
Our family also actively supports non-profit organizations involved with medical care for the homeless, climate change research, and education of the underserved.
HAS Chat with Dr. Xiling Shen: Professor and the Chief Scientific officer of the Terasaki Institute for Biomedical Innovation; Entrepreneur; founder and Chief Executive Officer of Xilis Inc.
Dr. Shen is currently a professor and the chief scientific officer of the Terasaki Institute for Biomedical Innovation and the founder and chief executive officer of Xilis Inc, which raised an $89M Series A to advance precision medicine.
He was formerly the Hawkins Family Associate Professor in the Department of Biomedical Engineering and the director of the Woo Center for Big Data and Precision Health at Duke University.
He received his BS, MS, and PhD degrees from Stanford University and the NSF career award at Cornell University. He was the steering committee chair of the NCI Patient-Derived Model of Cancer Consortium, co-chair of the NCI Tissue Engineering Consortium, and cancer track chair of Biomedical Engineering Society 2019. His lab studies precision medicine from a systems biology perspective. Areas of interest include cancer, stem cells, the gut-brain axis, and microbiome.
HAS Chat with Dr. Mary Lou Jepsenot: CEO and Founder of OPENWATER, a breakthrough medical technology developing game-changing treatments for cancer, stroke and mental disease; Innovator; named by Times Magazine as one of 100 most influential people in the world; CNN’s top 10 thinkers in science and technology; Forbes 50 over 50; co-founder of non-profit “One Laptop per Child”
Dr. Jepsen is CEO and Founder of Openwater, a breakthrough medical technology developing game-changing treatments for cancer, stroke and mental disease. She has been named as one of the 100 most influential people in the world by Time Magazine (“Time 100”), in addition to CNN’s top 10 thinkers in science and technology. She has over 250 patents published or issued to her name.
Previously, Dr. Jepsen served as the Executive Director of Engineering at Facebook and she has also held similar roles at Google. Prior to this, Dr. Jepsen was a professor at MIT and co-founded the non-profit organization “One Laptop per Child”, for which she served as CTO.
She also serves as a Director on both the Board of Lear Corporation, a Fortune 150 automotive components supplier, and Luminar Technologies, a pioneer in LiDAR and autonomous driving.